Navigation Links
Kuvan Receives Priority Review Status From Health Canada
Date:6/10/2009

is in clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the continued development and commercialization of Kuvan and BioMarin's other products and product candidates and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Kuvan; the content and timing of decisions by the U.S. Food and Drug Administration, Health Canada and other regulatory authorities concerning each of the described products and product candidates; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R), Naglazyme(R) and Kuvan(R) are a registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
2. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Kuvan Receives Marketing Approval in the European Union
5. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
10. IsoTis Receives FDA Clearance for Accell Family of Products
11. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 Fertility Associates of Memphis has ... USA , a network of more than 20 contributing ... patients have fast access to a national pool of ... . Fertility Associates of Memphis is the only fertility ... option. , Dr. William Kutteh , director of ...
(Date:12/19/2014)...  Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... a privately held company based in ... a big data platform for centralized management and ... proprietary on-market Genomic Management Solution, Bina-GMS 1 , ... fast and scalable analyses to maximize the value ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 Today, ... locate its pilot production facility and future company ... and produce innovative new materials that safely and ... not only because of its historic, strong support ... efforts to attract leading edge, technology-based companies such ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 In contrast ... of LEDs with various colors, Valoya uses proprietary LED ... This offers best possible uniformity which is critical in ... and high spectral accuracy throughout its lifetime which is ... LED tubes. , "The investment cost was clearly ...
Breaking Biology Technology:Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4
... Testing Market, FULLERTON, Calif., March 6 ... announced today that it has launched the ... integrated work cell which,consolidates chemistry and immunoassay ... to the company,s work cell family,combines Beckman ...
... Earlier Stage ... Chronic Kidney Disease Patients, CAMBRIDGE, Mass., March 6 ... launch of the phosphate binder,Renvela(R) (sevelamer carbonate) for dialysis patients, ... additional,approvals for the product., Genzyme has submitted a marketing ...
... SOUTH EASTON, Mass., March 6 Pressure,BioSciences, Inc. (Nasdaq: ... host,a teleconference to discuss its 2007 financial results and ... the teleconference either,by telephone or through a live web-cast. ... Wednesday March 12, 2008, Time: 4:30 p.m. Eastern ...
Cached Biology Technology:Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell 2Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients 2Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients 3Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients 4Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients 5Pressure BioSciences, Inc. to Discuss 2007 Financial Results and Provide Business Update 2
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... is a thermoplastic polyester which occurs naturally in bacteria ... . Even though PHB is biodegradable and is not ... too expensive to produce to replace petroleum-based plastics. New ... Microbial Cell Factories describes an alternative method of ...
... time, researchers have found a way to inject a precise ... living cell without a needle. The technique uses electricity ... and into a cell in a fraction of a second. ... University describe the technique in the online edition of the ...
... same time that a cell,s DNA gets duplicated, a third ... dense packing serves to repress or "silence" the DNA sequences ... the activity of nearby genes. When the cell divides, the ... cell,s DNA, but also the exact pattern in which that ...
Cached Biology News:Researchers do precise gene therapy without a needle 2Researchers do precise gene therapy without a needle 3Study reveals new role for RNA interference during chromosomal replication 2
... mL pipets ,Angled acrylic pipet rack offers easy ... round pipet cans. Constructed of 6 mm (1/4 in.) ... x 76 mm H x 289 mm D (3 ... mm W x 406 mm H x 292 mm ...
...
CoverWell imaging chamber gasket with adhesive, one chamber, 20 mm diameter, 1.0 mm deep *set of 40* Cell Biology Imaging Tools and Accessories Microscope Slide Accessories...
...
Biology Products: